Cat. No. Name Size Price Add Cart
KI0172Osi-9065 mg$272
Osi-90610 mg$432
Osi-90650 mg$1152
Osi-906200 mg$2672

Chemical Characteristic

Product NameOsi-906
SynonymsLinsitinib
CAS No.867160-71-2
Molecular Weight 421.49
FormulaC26H23N5O
Chemical Name(1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol
Smiles[C@]1(C[C@H](C1)c1n2c(c(ncc2)N)c(n1)c1ccc2ccc(nc2c1)c1ccccc1)(O)C
Chemical Structure

Biological activities

Osi-906 is a selective and orally efficacious dual inhibitor of the IGF-1 (insulin-like growth factor 1) receptor and insulin receptor (IR). The IC50 of osi-906 is 35 and 75 nM against IGF-IR and IR, respectively. Osi-906 inhibits IGF-1R-CHO cell line with an IC50 of 5 nM.[1] In cell-based phenotypic assays, osi-906 inhibits IGF-1- or IGF-2-mediated proliferation.[2] Osi-906 potently and selectively inhibits autophosphorylation of both human IGF-1R and IR. Osi-906 displays in vitro antiproliferative effects in a variety of tumor cell lines including Colo205, HT-29 and RKO cells. Osi-906 fully blocks IGF-1-stimulated receptor phosphorylation in the LISN cells.[3] Osi-906 demonstrates significant TGI (tumor growth inhibition) effects in multiple tumor xenograft models, including NIH-3T3/LISN, GEO, H295, and IGF-1R and IR DC models.[1] Uptake of 3H-2-deoxy glucose and 18FDG is significantly diminished following osi-906 exposure in sensitive tumor cells and subcutaneous xenografts (NCIH292) but not in an insensitive model lacking IGF-1R expression (NCI-H441).[4] Osi-906 in combination with bortezomib overcome bortezomib resistance in an in vivo model of myeloma.[5]

References

[1] Jin M, et al. Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution. Future Med Chem. 2012, 4(3): 315-328.
[2] Mulvihill MJ, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem. 2009, 1(6): 1153-1171.
[3] Mulvihill MJ, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem. 2009, 1(6): 1153-1171.
[4] McKinley ET, et al. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res. 2011, 17(10): 3332-3340.
[5] Kuhn DJ, et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma. Blood. 2012

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.
KareBayTM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.